Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Systemic anti-cancer therapy (SACT) after CDK 4/6 inhibitors for the treatment of metastatic / locally advanced breast cancer (SMC2807)

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Elacestrant for the treatment of postmenopausal patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with an activating oestrogen receptor 1 (ESR1) mutation, who have disease progression following at least one line of endocrine therapy including a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) (SMC2807) is being assessed for use by NHSScotland. 

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of systemic anti-cancer therapy (SACT) for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer who have disease progression, following at least one line of endocrine therapy including a CDK4/6i. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2807, to patients in Scotland.

The objectives were to:

• Determine the number of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer who have disease progression, following at least one line of endocrine therapy including a CDK 4/6i, and who go on to receive subsequent SACT.
• Describe the baseline characteristics of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer who have disease progression, following at least one line of endocrine therapy including a CDK 4/6i, and who go on to receive subsequent SACT.
• Provide information on use of prior and subsequent SACT for patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer who have disease progression following a CDK4/6i, and who go on to receive subsequent SACT.